Rajendran Alappan, MD
Nephrology · Columbus, GANPI 1225024557
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $55,554 of the $87,056 with a category attached, or 63.8%. 26 manufacturers reported payments, led by AstraZeneca at 57.6% of the total. Among nephrology clinicians in GA with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 272 payments — averaging $320.06 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$50K
- GSK$14K
- Akebia Therapeutics Inc$13K
- Fresenius USA Marketing, Inc.$4K
- Otsuka Pharmaceutical Development & Commercialization, Inc.$3K
- Bayer$334
- plus $2K from 20 others
Across 173 payments — averaging $1495.62 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Akebia Therapeutics Inc$214K
- GSK$34K
- AstraZeneca$11K
What the payments were for
- Consulting fees$19,31622%
- Speaking & faculty fees$55,55464%
- Travel & lodging$5,2276%
- Food & beverage$6,2237%
- Education$7371%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AstraZeneca(2 entities) | 99 | $50,123 |
| GSK | 17 | $13,839 |
| Akebia Therapeutics Inc | 25 | $12,887 |
| Fresenius USA Marketing, Inc. | 11 | $4,165 |
| Otsuka Pharmaceutical Development & Commercialization, Inc. | 2 | $3,430 |
| Bayer | 12 | $334 |
| Travere Therapeutics, Inc. | 23 | $311 |
| Amgen(2 entities) | 11 | $290 |
| OPKO Pharmaceuticals, LLC | 20 | $285 |
| Mallinckrodt Hospital Products Inc. | 8 | $236 |
| Baxter Healthcare | 5 | $206 |
| Novo Nordisk | 11 | $171 |
| Novartis | 7 | $141 |
| Otsuka America Pharmaceutical, Inc. | 4 | $135 |
| Mallinckrodt Enterprises LLC | 3 | $120 |
| Valeritas, Inc. | 1 | $90 |
| Calliditas Therapeutics US Inc. | 3 | $58 |
| Amarin Pharma, Inc. | 1 | $57 |
| Alnylam Pharmaceuticals Inc. | 2 | $35 |
| Boehringer Ingelheim | 1 | $25 |
| Aurinia Pharma U.S., Inc. | 1 | $24 |
| Vifor Pharma, Inc. | 1 | $23 |
| Kyowa Kirin, Inc. | 1 | $22 |
| Ardelyx, Inc. | 1 | $19 |
| Shire North American Group Inc | 1 | $17 |
| Fresenius USA Manufacturing, Inc. | 1 | $16 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$87,056 in reported general payments places this provider in the 95th percentile of 388 nephrology providers in Georgia.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| FarxigaDapagliflozin Propanediol | 106 | $97,780 |
| VelphoroSucroferric Oxyhydroxide | 25 | $63,731 |
| KerendiaFinerenone | 45 | $33,152 |
| JardianceEmpagliflozin | 16 | $21,546 |
| LokelmaSodium Zirconium Cyclosilicate | 22 | $9,742 |
| Paricalcitol | 40 | $8,657 |
| Sevelamer Carbonate | 16 | $3,569 |
| Midodrine Hcl | 39 | $3,519 |
| Calcitriol | 96 | $1,865 |
| Nifedipine ErNifedipine | 28 | $1,198 |
| Minoxidil | 20 | $712 |
| Potassium Chloride | 47 | $568 |
| Hydralazine Hcl | 25 | $566 |
| Bumetanide | 11 | $558 |
| Allopurinol | 75 | $494 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AstraZenecaFarxiga, Lokelma | $50,123 | $107,521128 claims |
| Fresenius USA Marketing, Inc.Velphoro | $4,165 | $63,73125 claims |
| BayerKerendia | $334 | $33,15245 claims |
| Boehringer IngelheimJardiance | $25 | $21,54616 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 388 nephrology providers in Georgia.
Other nephrology in Columbus
- Rajeev ChauhanColumbus$32K
- Sagar PanseMacon$542K
- Sheldon ShoreAtlanta$474K
- James TumlinLawrenceville$434K
- Salvatore ChillemiMarietta$287K
- Christina KleinAtlanta$137K
- Mary MuonekeAtlanta$119K
- Don WilliamsonAugusta$104K
- Frederic Rahbari OskouiAtlanta$88K
- William PaxtonLawrenceville$73K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.